REGN
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons...
Read moreDetails
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that...
Read moreDetails
Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for...
Read moreDetails
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman
SAN FRANCISCO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after...
Read moreDetails
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Jan. 10, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds...
Read moreDetails
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm,...
Read moreDetails
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
SAN FRANCISCO , Jan. 9, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after...
Read moreDetails
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman
SAN FRANCISCO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after...
Read moreDetails
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a class action was filed on behalf of...
Read moreDetails
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has...
Read moreDetails